Menú

GRECAP

RESPONSABLE DEL GRUP
GRENCAP - MIGUEL ANGEL MUÑOZ PEREZ
Miguel Angel Muñoz Pérez
mamunoz.bcn.ics@gencat.cat
avatar_grups_recerca.png

Projectes

Projectes del grup

Reproductibilitat ecogràfica dels criteris de voltatge d’HVE i de les alteracions del segment ST-T

  • Investigadors principals: Ernest Vinyoles Bargalló
  • Còdi: 4R08/008
  • Any d’inici: 2008
  • Finançadors: ICS - Institut Català de la Salut

Epidemiology of Heart Failure in Catalonia: a cohort study

  • Investigadors principals: Jordi Real Gatius, Xavier Mundet Tudurí, Ernest Vinyoles Bargalló, Mª Mar Domingo Teixidor, José Luis del Val García, José María Verdú Rotellar, Miguel Angel Muñoz Pérez
  • Còdi: 4R15/076
  • Any d’inici: 2015
  • Finançadors: Novartis Pharma AG

An International Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Outpatients in Early Stages of COVID-19

  • Investigadors principals: Pere Torán Monserrat, Ernest Vinyoles Bargalló
  • Còdi: INSIGHT 12
  • Any d’inici: 2021
  • Finançadors: University of Minnesota

AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2/3, DOUBLE-BLIND, 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332/RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID-19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS

  • Investigadors principals: Ernest Vinyoles Bargalló
  • Còdi: C4671002
  • Any d’inici: 2021
  • Finançadors:

A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, DOUBLE DUMMY, PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF07321332/RITONAVIR IN PREVENTING SYMPTOMATIC SARS-COV-2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF INDIVIDUALS WITH SARS-COV-2 INFECTION

  • Investigadors principals: Ernest Vinyoles Bargalló
  • Còdi: 5A21/023
  • Any d’inici: 2021
  • Finançadors:

Patronat

Col·laboradors

Acreditacions